Entia Biosciences (ERGO) 10-Q 2011 Q1 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

 QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period ended March 31, 2011

Commission File Number:  000-52864

 

Total Nutraceutical Solutions, Inc.

 (Exact name of small business issuer as specified in its charter)

Nevada	26-0561199
(State or other jurisdiction	(IRS Employer
of incorporation or organization)	Identification No.)

80 Columbia St., Stevenson, WA 98648

 (Address of principal executive offices)

(509) 427-5132

 (Registrant’s telephone number)

__________________________

 (Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes [X]  No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [  ]	Accelerated filer [  ]
Non-accelerated filer [  ]	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [  ] No [X]

On May 23, 2011, 61,362,470 shares of the registrant's common stock, par value $.001 per share, were outstanding.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION		3
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	19
PART II – OTHER INFORMATION		19
Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults Upon Senior Securities	19
Item 4.	[Removed and Reserved]	19
Item 5.	Other Information	19
Item 6.	Exhibits	20
SIGNATURES		22

- 2 -

PART I – FINANCIAL INFORMATION

Item1. Financial Statements

Total Nutraceutical Solutions, Inc.

March 31, 2011 and 2010

Index to Financial Statements

Contents                                                                                                                                                                                                         Page(s)

Balance Sheets at March 31, 2011  (Unaudited) and December 31, 2010

3

Statements of Operations for the Three Months Ended March 31, 2011 and 2010 (Unaudited)

4

Statement of Stockholders’ Equity for the Interim Period Ended March 31, 2011 (Unaudited)

5

Statements of Cash Flows for the Three Months Ended March 31, 2011 and 2010 (Unaudited)

6

Notes to the Financial Statements (Unaudited)

7

- 3 -

TOTAL NUTRACEUTICAL SOLUTIONS, INC.
CONSOLIDATED BALANCE SHEETS
				March 31, 2011		December 31, 2010
				(Unaudited)
Assets
Current Assets
	Cash		$	12,792	$	65,061
	Accounts receivable, net			23,393		10,469
	Inventory, net			173,064		177,098
	Prepaid expenses			61,550		37,814
	Current maturities of lease receivable			9,165		11,861
	Other current assets			15,044		14,950
		Total Current Assets		295,008		317,253
Property and Equipment, net				43,415		43,217
Patents and license, net				88,713		80,994
Lease receivable, net of current maturities				1,078		1,078
Total Assets			$	428,214	$	442,542
Liabilities and Stockholders' Equity (Deficit)
Current Liabilities:
	Accounts payable and accrued expenses		$	194,523	$	183,973
	Accrued compensation - officer			234,236		157,028
	Short-term convertible notes payable, net of discount-related party			31,250		25,000
	Short-term convertible notes payable, net of discount			190,000		170,000
	Notes payable			8,591		14,744
		Total Current Liabilities		658,600		550,745
Long Term Liabilities:
	Convertible notes payable, net of discount			37,029		196,950
		Total Long Term Liabilities		37,029		196,950
Total Liabilities				695,629		747,695
Stockholders' Equity (Deficit)
	Preferred stock, $.001 par value, 5,000,000 shares authorized,
		none issued or outstanding		-		-
	Common stock, $.001 par value, 70,000,000 shares authorized,
		61,632,470 and 58,362,470 shares issued and outstanding,		61,363		58,363
		respectively
	Additional paid-in capital			2,625,678		1,959,462
	Deferred compensation			(1,082)		(9,704)
	Advance on stock subscription			42,800		-
	Accumulated deficit			(2,996,174)		(2,313,274)
		Total Stockholders' Equity (Deficit)		(267,415)		(305,153)
Total Liabilities and Stockholders' Equity (Deficit)			$	428,214	$	442,542
See accompanying notes to the financial statements.

- 4 -

TOTAL NUTRACEUTICAL SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
				Three Months		Three Months
				Ending		Ending
				March 31, 2011		March 31, 2010
				(Unaudited)		(Unaudited)
REVENUES			$	84,237	$	24,898
COST OF GOODS SOLD				39,447		19,506
GROSS PROFIT				44,790		5,392
OPERATING EXPENSES
	Advertising and promotion			22,655		91,850
	Sales commissions			-		9,965
	Consulting fees - officer			30,000		30,000
	Professional fees			32,007		-
	Consulting fees			240,621		46,242
	Impairment of intangible asset			100,000		-
	General and administrative			227,450		86,531
		Total Operating Expenses		652,733		264,588
LOSS FROM OPERATIONS				(607,943)		(259,196)
OTHER (INCOME) EXPENSE
	Interest income			(136)		(277)
	Interest expense			75,093		42,916
		Total Other (Income) Expense		74,957		42,639
LOSS BEFORE TAXES				(682,900)		(301,835)
INCOME TAXES				-		-
NET LOSS			$	(682,900)	$	(301,835)
NET LOSS PER COMMON SHARE
	- BASIC AND DILUTED:		$	(0.01)	$	(0.01)
	Weighted common shares outstanding
		- basic and diluted		60,918,070		52,012,470
See accompanying notes to the financial statements.

- 5 -

TOTAL NUTRACEUTICAL SOLUTIONS, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
FOR THE YEAR ENDED DECEMBER 31, 2010 AND FOR THE INTERIM PERIOD ENDED MARCH 31, 2011
(UNAUDITED)
		Common				Additional				Advance				Total
		Stock		Par		Paid		Deferred		on Stock		Accumulated		Stockholders'
		Shares		Value		In Capital		Compensation		Subscription		Deficit		Equity
Balance - December 31, 2009		52,012,470		52,013		1,148,009		(20,303)		-	$	(1,046,959)	$	132,760
Issuance of warrants in connection with
	convertible notes payable					192,450								192,450
Beneficial conversion feature in connection with
	convertible note payable					194,950								194,950
Shares issued for cash in December 2010,
	net of offering costs of $1,500	3,050,000		3,050		25,870								28,920
Issuance of warrants in connection with the
	sale of common shares in December 2010					91,580								91,580
Issuance of warrants for future services						32,555		(32,555)
Issuance of common stock for services		3,300,000		3,300		274,048								277,348
Amortization of deferred compensation								43,154						43,154
Net loss												(1,266,315)		(1,266,315)
Balance - December 31, 2010		58,362,470	$	58,363	$	1,959,462	$	(9,704)	$	-	$	(2,313,274)	$	(305,153)
Advance on stock subscription										42,800				42,800
Issuance of warrants in connection with
	convertible notes payable					45,937								45,937
Beneficial conversion feature in connection with
	convertible note payable					167,030								167,300
Issuance of common stock for license agreement		1,000,000		1,000		99,000								100,000
Issuance of common stock for services		2,000,000		2,000		208,000								210,000
Stock compensation						146,249								146,249
Amortization of deferred compensation								8,622						8,622
Net loss												(682,900)		(682,900)
Balance - March 31, 2011		61,362,470	$	61,363	$	2,625,678	$	(1,082)	$	42,800	$	(2,996,174)	$	(267,415)
See accompanying notes to the financial statements.

- 6 -

TOTAL NUTRACEUTICAL SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
				Three Months		Three Months
				Ended		Ended
				March 31, 2011		March 31, 2010
				(Unaudited)		(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss			$	(682,900)	$	(301,835)
Adjustments to reconcile net loss to net cash
	used in operating activities:
	Depreciation			2,511		1,726
	Impairment of intangible asset			100,000
	Amortization of discount on convertible notes			66,796		39,327
	Stock-based compensation			364,870		13,741
	Changes in operating assets and liabilities:
		Accounts receivable		(12,924)		401
		Inventory		4,034		(32,996)
		Prepaid expenses		(23,736)		(39,268)
		Other current assets		(94)		(50,581)
		Accounts payable and accrued expenses		10,551		67,518
		Accrued compensation - officer		89,708		16,000
NET CASH USED IN OPERATING ACTIVITIES				(81,184)		(285,967)
CASH FLOWS FROM INVESTING ACTIVITIES:
	Advances under note receivable  - related party			-		(12,500)
	Purchase of property and equipment			(2,709)		(11,332)
	Acquisition of patents and patents pending, net			(7,719)		(16,596)
	Collections on lease receivable			2,696		729
NET CASH USED IN INVESTING ACTIVITIES				(7,732)		(39,699)
CASH FLOWS FROM FINANCING ACTIVITIES:
	Advance on stock subscription			42,800		-
	Proceeds from convertible notes payable			-		100,000
	Repayment of note payable			(6,153)		(6,196)
	Proceeds from convertible notes payable			-		450,000
NET CASH PROVIDED BY FINANCING ACTIVITIES				36,647		543,804
NET CHANGE IN CASH				(52,269)		218,138
Cash at beginning of period				65,061		48,141
Cash at end of period			$	12,792	$	266,279
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
	Interest paid		$	136	$	464
	Taxes paid		$	-	$	-
SUPPLEMENTAL DISCLOSURE OF NONCASH FLOWS FINANCING
	AND INVESTING ACTIVITIES:
	Stock issued for license		$	100,000	$	-
	Warrants issued in connection with notes payable		$	45,937	$	-
	Warrants issued for future services		$	-	$	18,750
See accompanying notes to the financial statements.

- 7 -

Total Nutraceutical Solutions, Inc.

March 31, 2011 and 2010

Notes to the Consolidated Financial Statements

(Unaudited)

NOTE 1 - ORGANIZATION AND OPERATIONS

Generic Marketing Services, Inc. was incorporated on July 19, 2007 under the laws of the State of Nevada as a subsidiary of Basic Services, Inc., also a Nevada corporation.   On December 31, 2007, Basic Services spun off Generic Marketing Services.  On October 8, 2008, Generic Marketing Services changed its name to Total Nutraceutical Solutions, Inc. (TNS, the company, us, we, or our).  We engage in the distribution of organic dietary supplement nutraceutical products in the United States of America.

On March 26, 2010 we entered into a Profit Sharing Agreement or Direct Marketing Affiliates Project (DMAP) with American Charter & Marketing LLC (ACM) and Delta Group Investments Limited (DGI), with the primary focus of undertaking a direct mail marketing campaign designed to sell nutraceutical products developed and manufactured by TNS.  We acted as Managing Affiliate.  DGI provided $300,000 in the form of a loan, as starting capital for the project.   The net profits of the DMAP project were to be shared with 25% going to the Company, 25% to DGI, 25% to ACM and 25% as a return on the initial loan.  This agreement was terminated subsequent to December 31, 2010, effective February 17, 2011.

While the Company is attempting to generate sufficient revenues, our cash position may not be sufficient to support our daily operations.  Management intends to raise additional funds by way of a public or private offering.  Management believes that the actions presently being taken to generate sufficient revenues provide the opportunity for the Company to continue as a going concern.  While we believe in the viability of our strategy to generate revenues and in our ability to raise additional funds, there can be no assurances to that effect.  The ability of the Company to continue as a going concern is dependent upon our ability to generate sufficient revenues.

The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and principles of consolidation

The accompanying consolidated unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-Q and Article 8 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented.  Unaudited interim results are not necessarily indicative of the results for the full year.  These unaudited interim financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2010 and notes thereto contained in the information as part of the Company’s Annual Report on Form 10-K filed with the SEC on May 18, 2011.

The consolidated financial statements include all accounts of TNS as of March 31, 2011 and 2010 and for the interim periods then ended; and all accounts of DMAP as of February 17, 2011 and for the period from March 26, 2010 (inception) through December 31, 2010.  All inter-company balances and transactions have been eliminated.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

- 8 -

Inventory

Inventory, which consists primarily of raw materials to be used in the production of our dietary supplement products, is stated at the lower of cost or market using the first-in, first-out method. We regularly review our inventory on hand and, when necessary, record a provision for excess or obsolete inventory.  The inventory reserve was $149,602 at March 31, 2011 and December 31, 2010, respectively.

Discount on convertible notes payable

We allocate the proceeds received from convertible notes between convertible notes payable and warrants, if applicable. The resulting discount for warrants is amortized using the effective interest method over the life of the debt instrument. After allocating a portion of the proceeds to the warrants, the effective conversion price of the convertible note payable can be determined. If the effective conversion price is lower than the market price at the date of issuance, a beneficial conversion feature is recorded as an additional discount to the convertible note payable. The beneficial conversion feature discount is amortized using the effective interest method over the life of the debt instrument.  The amortization is recorded as interest expense on the consolidated statement of operations.

Derivatives embedded in certain debt securities

We evaluate financial instruments for freestanding or embedded derivatives.  Derivative instruments that have been separated from the host contract and do not qualify for hedge accounting are recorded at fair value with changes in value recognized as other income (expense) in the consolidated statements of operations.

Fair value of financial instruments

We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
Level 3	Unobservable inputs where there is little or no market data, which require the reporting entity to develop its ownassumptions.

The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, prepaid expenses, accounts payable and accrued officer’s compensation, approximate their fair values because of the short maturity of these instruments.  Our lease receivable, notes payable and convertible notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to TNS for similar financial arrangements at March 31, 2011 and 2010.

We do not have any assets or liabilities measured at fair value on a recurring or a non-recurring basis. Consequently, we did not have any fair value adjustments for assets and liabilities measured at fair value at March 31, 2011 or 2010, nor any gains or losses reported in the consolidated statement of operations that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date for the periods ended March 31, 2011 and 2010.

Revenue recognition

We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectibility of amounts is reasonably assured.

Revenues from the sale of products, including shipping and handling fees but excluding statutory taxes collected from customers, as applicable, are recognized when shipment has occurred. We sell our products directly to customers.  Persuasive

- 9 -

evidence of an arrangement is demonstrated via order and invoice, product delivery is evidenced by a bill of lading from the third party carrier and title transfers upon shipment, the sales price to the customer is fixed upon acceptance of the order and there is no separate sales rebate, discount, or volume incentive.

Equity instruments issued to parties other than employees for acquiring goods or services

We account for all transactions in which goods or services are the consideration received for the issuance of equity instruments based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.  The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur.  Currently such transactions are primarily awards of warrants to purchase common stock.

The fair value of each warrant award is estimated on the date of grant using a Black-Scholes option-pricing valuation model.  The assumptions  used to determine the fair value of our warrants are as follows:

· The expected life of warrants issued represents the period of time the warrants are expected to be outstanding.

· The expected volatility is based on  the historical volatility of comparable companies’ stock over the contractual life of the warrant.

· The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the warrant.

· The expected dividend yield is based on our current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the warrant.

Net loss per common share

Basic and diluted net loss per share has been computed by dividing our net loss by the weighted average number of common shares issued and outstanding. Options and warrants to purchase our common stock as well as debt which is convertible into common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share for 2011 and 2010. The following table presents a reconciliation of basic and diluted loss per share:

		For the Period Ended March 31,
		2011			2010
Numerator:
	Net loss applicable to common shareholders	$	(682,900	)	$	(301,835	)
Denominator:
	Weighted-average common shares outstanding		60,918,070			52,012,470
	Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)
Common stock warrants			14,652,800			10,405,800
Convertible debt including interest			6,879,063			2,465,625
Excluded dilutive securities			21,531,863			2,871,425

Reclassifications 

Certain reclassifications have been made to prior period financial statements and footnotes in order to conform to the current period's presentation.

Segments

We have determined that we operate in one segment for financial reporting purposes.

- 10 -

Recently issued accounting pronouncements

        In October 2009, the FASB issued new authoritative guidance to require companies to allocate revenue in multiple-element arrangements based on an element's estimated selling price if vendor-specific or other third-party evidence of value is not available. The new guidance is effective for revenue transactions entered into during fiscal years beginning on or after June 15, 2010, with earlier application permitted. The early adoption of this guidance did not have a material impact on our consolidated financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

NOTE 3 – INVENTORY

Inventory at March 31, 2011 and December 31, 2010 consisted of the following:

	March 31, 2011		December 31, 2010
Raw materials	$	285,813	$	293,391
Finished goods		36,853		33,309
		322,666		326,700
Less reserve for excess and obsolete inventory		(149,602)		(149,062)
	$	173,064	$	177,098

NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment, stated at cost, less accumulated depreciation at March 31, 2011 and December 31, 2010 consisted of the following:

	March 31, 2011		December 31, 2010
Office equipment	$	22,072	$	19,364
Production equipment		30,964		30,964
Leasehold improvements		2,192		2,192
		55,228		52,520
Less accumulated depreciation		(11,813)		(9,303)
	$	43,415	$	43,217

NOTE 5 – NOTE PAYABLE

Note payable at March 31, 2011 and December 31, 2010 consisted of the following:

	March 31, 2011		December 31, 2010
On November 18, 2010 we entered into a short term financing agreement for principal of $13,810 for director’s and officer’s insurance.  Payments are due monthly, with interest at 4.85% per annum.	$	7,603	$	12,300
On August 11, 2010 we entered into a short term financing agreement for principal of $4,796 for product liability insurance.  Payments are due monthly, with interest at 9.65% per annum.		988		2,444
	$	8,591	$	14,744

NOTE 6 – SHORT-TERM CONVERTIBLE NOTE PAYABLE

- 11 -

Proceeds from the issuance of $250,000 from short-term convertible promissory notes and warrants were allocated between the notes and warrants on a relative fair value basis.  The issuance of $250,000 includes one $100,000 promissory note that bears interest at 6% per annum and matured on December 31, 2010.  We are currently negotiating an extension to this note.  In addition, two promissory notes were issued with principal of $100,000 and $50,000 which bear interest at 6% per annum and mature on December 31, 2011.  The total value allocated to the warrants was approximately $123,750.  The fair value of the warrants was determined using the Black-Scholes option pricing model based on the following assumptions: expected dividend yield of 0%, risk-free interest rate of 2.46 – 2.49%, volatility of 72.67 – 78.08% and a contractual life of 5 years.  The value of the warrants was recorded as a debt discount against the proceeds of the notes.  In addition, the beneficial conversion features related to the notes were determined to be approximately $126,250.  As a result, the total discount on the notes totaled $250,000, and is being amortized over term of the notes.  Amortization of debt discount of approximately $45,600 and $10,000 was recorded for the three months ending March 31, 2011 and 2010, respectively. 

NOTE 7 – CONVERTIBLE NOTES PAYABLE - RELATED PARTIES

Proceeds from the issuance of a $50,000 convertible promissory note and warrants from related parties was allocated between the notes and warrants on a relative fair value basis.  This note bears interest at 6% per annum and matures on December 31, 2011.  The related party note holders are (i) Marvin Hausman, M.D., Chief Executive Officer, Director and Stockholder of TNS and (ii) Philip Sobol, a Director of the TNS.  The total value allocated to the warrants was approximately $22,200.  The fair value of the warrants was determined using the Black-Scholes option pricing model based on the following assumptions: expected dividend yield of 0%, risk-free interest rate of 2.69%,volatility of 80.52% and a contractual life of 5 years.  The value of the warrants was recorded as a debt discount against the proceeds of the note.  In addition, the beneficial conversion feature related to the note was determined to be approximately $27,800.  As a result, the total discount on the note totaled $50,000, and is being amortized over term of the note.  Amortization of debt discount of approximately $6,250 was recorded for three months ending March 31, 2011 and 2010, respectively. 

NOTE 8 – CONVERTIBLE NOTES PAYABLE

Proceeds from the issuance of a $312,500 convertible promissory note and warrants were allocated between the note and warrants on a relative fair value basis.  This note bears interest at 5% per annum and matures on June 30, 2012.  This note was issued in replacement of a $300,000 convertible promissory note which had a maturity date of March 26, 2013.  The total value allocated to the warrants was approximately $45,900.  The fair value of the warrants was determined using the Black-Scholes option pricing model based on the following assumptions: expected dividend yield of 0%, risk-free interest rate of 1.05%, volatility of 192.8% and a contractual life of 3 years.  In addition, approximately $49,900 of the value of the warrants issued under the previous note remained unamortized. The value of the warrants was recorded as a debt discount against the proceeds of the note.  The beneficial conversion feature related to the note was determined to be approximately $216,600.  As a result, the total discount on the note totaled $312,500, and is being amortized over term of the note.  Amortization of debt discount of approximately $40,500 and zero was recorded for 2011 and 2010, respectively. 

NOTE 9 – RELATED PARTY TRANSACTIONS

Consulting services from Chairman and CEO

Consulting services provided by and compensation to the Chairman and CEO were $30,000 for the three months ended March 31, 2011 and 2010, respectively.

Receivables from and payables to Related Parties

During the first quarter of 2010 we loaned $12,500 to one of the principals of ACM, Gary Ballen. ACM is one of the affiliates of the DMAP. In the quarter ended December 31, 2010 we determined that this loan was uncollectible and established a reserve for the entire amount of the loan.

- 12 -

NOTE 10 – STOCKHOLDERS’ EQUITY

Common stock

On August 26, 2010, we entered into a consulting agreement for marketing services.  Under this agreement the consultant will provide certain marketing services in exchange for 4,000,000 shares of our common stock valued at $420,000 at the date of grant, based upon the stock price on the grant date.  2,000,000 shares were issued at signing 2,000,000 shares were issued on January 3, 2011.

On February 3, 2011, our board of directors approved a grant of 1,000,000 shares of common stock to a third party in consideration for an Assignment and Assumption Agreement.  The stock was valued at $70,000 at the date of grant based upon the stock price on the grant date.  The shares were issued in April, 2011.

Stock incentive plan

During the first quarter of fiscal 2011, we granted 2,379,998 options under our 2010 Stock Incentive Plan with a contractual term of 10 years and an aggregate fair value on the date of grant of $231,465.  The vesting schedule of these options ranges from immediate vesting to vesting over two years.

Stock-based compensation expense is recognized using the straight-line attribution method over the optionees’ requisite service period.  Stock-based compensation expense of approximately $146,250 and zero was recorded for three months ending March 31, 2011 and 2010, respectively, as a component of general and administrative expense.    

We use the Black-Scholes option-pricing model to determine the fair value of options on the date of grant.  In determining the fair value of options, we employed the following key assumptions.  There were no stock option grants during the quarter ended March 31, 2010:

	Three months ended
	March 31, 2011
Expected dividend yield		—
Expected stock price volatility		187.22% - 187.30	%
Risk-free interest rate		1.98% – 2.03	%
Expected term (in years)		5 – 5.4 years
Weighted-average grant date fair-value	$	0.097

Warrants

During the first quarter of fiscal 2010, we issued warrants to purchase 125,000 shares of common stock under agreements for consulting services. These warrants have exercise prices of $0.25 per share and have terms of five years.  There were no warrants issued under agreements for consulting services in the first quarter of fiscal 2011.  The fair value of the warrants issued under consulting agreements is recorded as deferred compensation. The amortization of deferred compensation is recorded as consulting expense and was $8,621 and $13,741 for the three months ending March 31, 2011 and 2010, respectively.

During the first quarter of fiscal 2011, we issued warrants to purchase 600,000 shares of common stock at $0.12 per share in conjunction with the issuance of convertible promissory notes.  The warrants have a term of three years.   The fair value of these warrants was recorded as debt discount.  The amortization related to these warrants is recorded as interest expense and was $40,546 and zero for the three months ending March 31, 2011 and 2010, respectively.

During the first quarter of fiscal 2010, we issued warrants to purchase 1,250,000 shares of common stock at $0.10 per share in conjunction with the issuance of convertible promissory notes. The warrants have as term of five years. The fair value of these warrants was recorded as debt discount.  The amortization related to these warrants is recorded as interest expense and was $22,556 and $16,325 for the three months ending March 31, 2011 and 2010, respectively.

During the first quarter of fiscal 2010, we issued warrants to purchase 600,000 shares of common stock at $0.15 per share in conjunction with the issuance of convertible promissory notes. The warrants have as term of three years. The fair value of these warrants was recorded as debt discount. The amortization related to these warrants is recorded as interest expense and was $5,725 and zero for the three months ending March 31, 2011 and 2010, respectively.

- 13 -

We use the Black-Scholes option-pricing model to determine the fair value of warrants on the date of grant. In the first quarter of fiscal 2011, we changed the methodology for determining certain inputs to the Black-Scholes model. The methodology for determining the volatility was changed from using an average volatility of comparable companies within TNS’ industry to using an average of TNS’ volatility and the comparable companies’ volatility. There were no changes to the methodology for determining the remaining Black-Scholes inputs.

We use the Black-Scholes option-pricing model to determine the fair value of warrants on the date of grant.  In determining the fair value of warrants, we employed the following key assumptions:

	Three months ended	Three months ended
	March 31, 2011	March 31, 2010
Expected dividend yield	—		—
Expected stock price volatility	192.80%		72.67	%
Risk-free interest rate	1.05%		2.65	%
Expected term (in years)	3 years		5 years
Weighted-average grant date fair-value	$ 0.09		$0.15

NOTE 11 – SUBSEQUENT EVENTS

We have evaluated all events that occurred after the balance sheet date of March 31, 2011 through May 23, 2011, the date when the financial statements were issued to determine if they must be reported.  We determined that there were no reportable subsequent events to be disclosed.

- 14 -

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information

We may from time to time make written or oral "forward-looking statements" including statements contained in this report and in other communications, which are made in good faith by us pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements include statements of our plans, objectives, expectations, estimates and intentions, which are subject to change based on various important factors (some of which are beyond the Company's control).  The following factors, in addition to others not listed, could cause our actual results to differ materially from those expressed in forward looking statements: the strength of the domestic and local economies in which the Company conducts operations, the impact of current uncertainties in global economic conditions and the ongoing financial crisis affecting the domestic and foreign banking system and financial markets, including the impact on our suppliers and customers, changes in client needs and consumer spending habits, the impact of competition and technological change on our company, our ability to manage its growth effectively, including its ability to successfully integrate any business which it might acquire, and currency fluctuations. All forward-looking statements in this report are based upon information available to us on the date of this report.  We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

The following discussion and analysis should be read in conjunction with our financial statements and the notes thereto appearing in Part I, Item 1.

Overview of Current Operations

Total Nutraceutical Solutions, Inc. (TNS) is an emerging biotechnology company engaged in the discovery, formulation, and marketing of natural ingredients that can be used in organic nutraceutical and cosmetic products developed and sold by TNS and by third parties.  Our current portfolio of ingredients includes ERGO D2, vitamin D, L-Ergothioneine, beta-glucans, polyphenols and curcumin.  These highly potent antioxidants provide multiple health benefits for both humans and animals and address multi-billion dollar markets for inflammation control, immune system support, increased energy and stamina, reduced stress and anxiety, and hair and nail growth.  Mushroom dietary supplements have the nutritional potential to provide multiple health benefits for humans, including providing antioxidants, reducing inflammation, supporting the immune system, promoting healthy joints, increasing stamina, and reducing stress and anxiety.  We develop production and analytic technologies for food and nutritional supplements composed primarily of mushrooms.  We naturally enhance the vitamin D content of mushrooms supplied by domestic growers, utilizing TNS patent pending proprietary UV-light methodology at our Sherwood, Oregon facility.  In addition to preventative healthcare formulations and nutritional approaches to a wide variety of human conditions and illnesses, we also develop and acquire nutritional tools and products in the fields of animal husbandry and livestock feeds.

We also use our ingredients in nutraceutical products that we formulate and market to consumers.  We have developed mushroom based nutraceutical dietary supplement products that are made entirely of naturally occurring dietary substances which are manufactured under contract by third party contractors, Columbia Nutritional Services, Inc. of Vancouver, Washington and Pro-Tech Laboratories of Quitman, Texas.  We currently market four natural organic nutraceutical mushroom dietary supplement products, ImmuSANO and GlucoSANO for human consumption, Gröh, which has been designed to nutritionally support hair follicles and  nail beds, and EquiSANO for the equine market.  These naturally occurring dietary substances have not been chemically altered, and we believe these products have both health benefits and mass appeal to people wanting natural and non-toxic nutritional-based healthcare.  We sell our ingredients directly to manufacturers of cosmetic and nutraceutical products and indirectly through resellers.  We market and sell our consumer products directly to consumers utilizing network marketing programs, direct mail order, internet marketing, and commission sales people and indirectly through resellers.  Our current portfolio of consumer products include proprietary formulations of over the counter mushroom based nutraceutical products produced by outside contract manufacturers.  Fulfillment and distribution is performed at facilities in Stevenson, Washington, Sherwood, Oregon and Quitman, Texas.

We utilize novel clinical models, biomarkers, and analytical tools to validate the nutritional and clinical efficacy of our ingredients and the products that incorporate them.  Our scientific strategy and technology platform initially focused on the unique manufacturing and health benefits of specific bioactive nutrients found in certain whole natural mushrooms and their mycelial biomasses (mushroom powder and its active components).  In early 2011, we expanded into curcumin extracted from tumeric.  

- 15 -

Research and development of new ingredients and nutraceutical products are also performed under contract with outside laboratories, such as the Department of Food Science, Pennsylvania State University.

In March 2010 we entered into a Profit Sharing Agreement with American Charter and Marketing LLC and Delta Group Investments Limited under which we agreed to form an association referred to as the Direct Marketing Affiliates Project (“DMAP”).  Pursuant to the agreement the parties agreed to work together to undertake a direct mail campaign designed to sell TNS nutraceutical products for a period of three years, with the day to day management and control of business operations of the association being vested in TNS as the managing affiliate.  Between March 2010 and February 2011, six nutraceutical products under the NuFlex trademark were marketed and sold through the DMAP for joint support and joint pain.  The six products were NuFlex LTR (Long Term Relief), NuFlex IR (Instant Relief, a topical spray for muscle aches and strains), NuFlex AF (Accelerator Formula, to boost the long term benefits of NuFlex long term relief formula), NuFlex Advanced Joint Repair NuFlex Multi Joint Support and NuFex MSM.  These products were produced by Pro-Tech Laboratories of Quitman, Texas and Columbia Nutritional Services of Vancouver, Washington and were sold through direct marketing contract vendors.  In February 2011 the parties to the Profit Sharing Agreement agreed to terminate the DMAP leaving TNS in possession of the property and assets of the DMAP.  

In February 2009 we signed an Agreement for Removal of Mushroom Substrate Waste with Hokto Kinoko Co. to acquire mushroom spent substrate from the Hokto Kinoko 250,000 square foot mushroom growing facility in San Marcos, California.  The facility, which is designed to produce fresh specialty mushrooms, has the potential at full capacity to produce 20-25 tons of spent substrate per day.  Mushroom substrate waste is defined as the spent substrate (growing media) and all mushroom residuals resulting from cleaning the growing bottles after the harvest of mushroom fruit bodies at the growing facility.  The Hokto state-of-the-art facility, the largest of its kind in the United States, produces the following mushrooms:  Brown Beech (Buna Shimeji), White Beech (Bunapi), King Trumpet (Pleurotus eryngii), and Maitake.  

Under the agreement we purchased an auger and other related equipment to facilitate collection and removal of the mushroom substrate and we are leasing that equipment to Hokto Kinoko on a monthly basis at $944 per month.  Golden Gourmet Mushrooms personnel used the facilities on the Hokto Kinoko premises to grow mushrooms and also supervised the use of the auger for collection and removal of the mushroom substrate.  The mushroom substrate waste is sold by TNS to Evergreen Nurseries, San Diego, California.  Golden Gourmet Mushrooms has changed its name to M2i.  Under the terms of an amendment to the Agreement Removal of Mushroom Substrate Waste with Hokto Kinoko signed in March 2011 TNS shares the gross proceeds of its sales of mushroom substrate to Evergreen Nurseries with Hokto Kinoko and M2i on an equal basis.

Quarterly Highlights

In January 2011, we issued 2,000,000 shares of common stock to Keith Manfred under a Consulting Agreement dated August 26, 2010 pursuant to which Mr. Manfred has performed various marketing services to TNS.  

Effective January 26, 2011, we entered into a convertible note payable with Delta Group Investments Limited (DGI) which replaces the convertible note payable with DGI dated March 26, 2010.  This convertible note payable is in the amount of $312,500 and bears interest at 5% per year and expires on June 30, 2012.  DGI has the option to convert the outstanding note into TNS restricted common shares at $0.06 per share at any time prior to payment in full of the principal balance of the convertible note payable. In connection with the issuance of the convertible note payable, we granted DGI a warrant to purchase 600,000 common shares exercisable at $0.12 per share expiring 3 years from the date of issuance.

On Jaunary 27, 2011 TNS entered into an Investment Banking and Business Development Agreement with Corporate Finance Resources, Inc. (CFR) under which will serve as a non-exclusive placement agent concerning private placements, business combinations and business development transactions (such as customer, vendor, supplier or distributor arrangements).  Under the agreement TNS will compensate CFR with cash and equity fees in relations to transactions which are not excluded from the investment banking agreement with CFR.  In addition TNS agreed to issue seven year warrants to purchase one million shares of common stock at $0.10 per share to CFR, with 25% becoming exercisable upon the effective date of the agreement, 25% upon the date that offering materials for a private placement are first distributed, 25% upon the date that a covered transaction occurs and consideration is paid upon closing and the final 25% (or 100% if some of the earlier milestones had not occurred yet) upon the earlier to occur of the receipt of $500,000 in consideration from a closing or the expiration, suspension or termination of a covered private placement offering.  Subsequently CFR agreed to delay the initial issuance of the warrants until May 31, 2011.  No warrants have been issued under this agreement to date.

- 16 -

Effective February 17, 2011, we entered into a Termination of Profit Sharing Agreement, whereby the DMAP was terminated.  Per this termination agreement, all assets and property of the DMAP were transferred to TNS.  As managing affiliate of the DMAP, TNS was responsible for the wind up the activities of the DMAP.

On March 15, 2011 we entered into two lease agreements with Sherwood Venture LLC for premises located at 1499 S.W. Tualatin-Sherwood Road, Sherwood, Oregon 97140, with both leases terminating on May 31, 2012.  With the two new leases, TNS will pay an aggregate of $1,950 per month for 3,520 square feet of office and warehouse space.

In April 2011 we issued 1,000,000 shares to MSH Ventures pursuant to an Assignment and Assumption Agreement between TNS and MSH Ventures dated October 26, 2009 under which MSH Ventures assigned all of its rights to an Exclusive License Agreement with the University of Cologne in Germany pertaining to a patent application entitled “Identification of Ergothioneine Transporter and Therapeutic Uses Thereof.”  Our President and Chief Executive Officer, Marvin S. Hausman, M.D. owns a 66% equity interest in MSH Ventures.

Results of Operations for the quarter ended March 31, 2011

During the three months ended March 31, 2011, we had a net loss of $(682,900) versus a $(301,835) net loss for the same period last year.  The increase in the net loss was primarily attributable to increased operating expenses.   Our total operating expenses increased from $264,588 for the three months ended March 31, 2010 to $652,734 for the three months ended March 31, 2011.  This increase was due primarily to an increase in consulting fees primarily due to expenses related to a consulting arrangement whereby we issued shares of our common stock in exchange for certain marketing services, an increase in general and administrative expense due to stock compensation expense related to the issuance of stock options, and impairment expense related to the write-off of an intangible asset..  Total  liabilities decreased modestly from $747,695 at December 31, 2010 to $695,628 for the three months ended March 31, 2011.  

Revenues

Revenues and Cost of Goods Sold (in thousands, except percentages):

	For the Quarters Ended March 31,				Change
	2011		2010		$		%
Revenues	$	84	$	25	$	59		70%
Cost of Goods Sold		39		20		19		49%

Revenues.  Revenues are generated primarily from the sale of our mushroom based nutraceutical dietary supplement products.  We generated $84,237 in revenues for the three months ended March 31, 2011 as compared to $24,898 in revenues for the same period last year.  The increase in revenues was primarily due to the increase in the number of products we are marketing and the addition of our ingredients business.  Revenues increased in quarter ended March 31, 2011 compared to the quarter ended March 31, 2010 primarily because in the first quarter of 2010 we sold only three mushroom supplement products, whereas in first quarter of 2011, we were selling a fourth mushroom supplement product, Groh, as well as the NuFlex product line, and natural ingredients that can be used in organic nutraceutical and cosmetic products.  Overall, approximately 21% of our revenues came from sales of GlucoSANO and ImmunoSANO, 19% from sales of Nu-Flex products, 18% from sales of Groh, 17% from sales of EquiSANO, 11% from sales of bulk mushroom substrate and 9% from sales of ingredients.

Cost of Goods Sold.    Cost of goods sold includes raw materials such as nutraceutical mushrooms, as well as production costs for manufacturing our supplement products.  Our cost of goods sold was $39,447 for the quarter resulting in a gross profit of $44,790 as compared to a cost of goods sold of $19,506 and a gross profit o f $5,392 for the three months ended March 31, 2010.  Cost of goods sold as a percentage of revenue decreased from 80% in fiscal year 2010 to 46% in fiscal year 2011.  Our cost of goods as a percentage of revenue for first quarter of 2011 decreased from the first quarter of 2010as our production processes have become more efficient in our second year of production.

- 17 -

Going Concern

Our independent auditors have included an explanatory paragraph in their report on the 2010 financial statements regarding substantial doubt about our ability to continue as a going concern.  Our 2010 financial statements contain additional note disclosure describing the circumstances that lead to this disclosure by our independent auditors.

Expected purchase or sale of plant and significant equipment

We do not anticipate the purchase or sale of any plant or significant equipment; as such items are not required by us at this time.

Significant changes in the number of employees

As of March 31, 2011, we did not have any employees.  Our Chief Executive Officer, Marvin S. Hausman, M.D. and our Vice President for Marketing and Sales, Devin Andres each provide employee like services pursuant to consulting arrangements.  As our operations expand, we anticipate the need to hire employees however, the exact number of employees that would be hired is not quantifiable at this time.

Liquidity and Capital Resources

As of March 31, 2011 we had cash of $12,792 as compared with cash of $65,061 on December 31, 2010.  We have incurred debts in an aggregate principal amount of $612,500 at various rates of interest, of which $100,000 plus 6% interest matured on December 31, 2010 and remains unpaid.  The restructuring of this debt is under negotiation.  In preparation for the termination of the DMAP in February 2011, effective on January 26, 2011 we restructured $300,000 of debt plus accrued interest of $12,500 with a maturity date of March 26, 2013 with Delta Group Investments, one of the DMAP partners, creating a new promissory note in the principal amount of $312,500 plus interest at 5% and a maturity date of June 30, 2012.  The rest of the debt in the aggregate principal amount of $200,000 plus interest at 6% matures on December 31, 2011.  Given the revenues received after the quarter end, management believes it has sufficient funds to remain operational through June 2011.

We anticipate that we will continue to generate losses during the remainder of this fiscal year and therefore, unless we are able to raise capital through equity private placements we may be unable to continue operations in the future.  We have undertaken a private placement of units consisting of shares and common stock purchase warrants starting in January 2011 which we expect to close at the end of May 2011.  Additional working capital may also be sought through additional notes payable to banks or related parties (officers, directors or stockholders), or from other available funding sources at market rates of interest, or a combination of these.  The ability to raise necessary financing will depend on many factors, including the nature and prospects of any business to be acquired and the economic and market conditions prevailing at the time financing is sought.  

There can be no assurance that additional debt or equity capital will be available to us.  We currently have no agreements, arrangements, or understandings with any person to obtain funds through bank loans, lines of credit, or any other sources.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations", included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

New Accounting Standards

Please see Note 2 of the Notes to Financial Statements in this quarterly report concerning new accounting standards.

- 18 -

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

Not required

Item 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this Quarterly Report on Form 10-Q, an evaluation was carried out by our management, with the participation of our Chief Executive Officer who is also our principal financial and accounting officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 31, 2011.  Based on that evaluation, our principal executive officer and principal financial officer concluded that the material weaknesses identified in our management report on internal controls and procedures contained in our Form 10-K for the fiscal year ended December 31, 2010, Item 9A filed on May 18, 2011 still exist, and therefore our disclosure controls and procedures were not effective as of March 31, 2011.

Changes in Internal Control Over Financial Reporting

As of the end of the quarter ended March 31, 2011, there have been no changes in internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) during the quarter ended March 31, 2011, that materially affected, or are reasonably likely to materially affect, our company’s internal control over financial reporting.

Part II. OTHER INFORMATION

Item 1.  Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.  However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

We are not presently a party to any material litigation, nor to the knowledge of management is any litigation threatened against us, which may materially affect us.

Item 1A.  Risk Factors

See Risk Factors set forth in Part I, Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010, and the discussion above in Part I, Item 2, under " Liquidity and Capital Resources.”

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds 

None.

Item 3.  Defaults Upon Senior Securities

None.

Item 4.  Submission of Matters to a Vote of Security Holders

None.

Item 5.  Other Information

None.

- 19 -

Item 6.  Exhibits 

Exhibit Number	Description of Exhibit	Filed Herewith	Form	Exhibit	Filing Date
3.1	Amended and Restated Articles of Incorporation of Registrant		8-K	3.1	10/29/2010
3.2	Amended and Restated Bylaws of Registrant		8-K	3.2	09/22/2010
3.3	Amended Articles of Merger Incorporation as currently in effect		8-K	3.3	10/13/2008
10.1	Exclusive Option Agreement dated May 1, 2006, between The Penn State Research Foundation and Northwest Medical Research Inc.		8-K	10.1	09/04/2008
10.2	Assignment Agreement to the Option Agreement, dated July 31, 2008, among The Penn State Research Foundation, Northwest Medical Research Inc. and Generic Marketing Services, Inc.		8-K	10.2	09/04/2008
10.3	Assignment and Assumption Agreement, dated July 31, 2008, between Northwest Medical Research Inc. and Generic Marketing Services, Inc.		8-K	10.3	09/04/2008
10.4	Form of Common Stock and Warrant Purchase Agreement		8-K	10.1	06/12/2009
10.5	Form of Securities Purchase Agreement		8-K	10.1	09/21/2009
10.6	$50,000 Promissory Note between TNS and Marvin S. Hausman, M.D. and Philip Sobol dated December 30, 2009		8-K	10.1	12/31/2010
10.7	$100,000 Promissory Note between TNS and Larry A. Johnson dated January 12, 2010		8-K	10.1	2/24/2010
10.8	$100,000 Promissory Note between TNS and Mark C. Wolf dated February 18, 2010		8-K	10.2	2/24/2010
10.9	$50,000 Promissory Note between TNS and Mark C. Wolf dated February 18, 2010		10-K	10.9	4/15/2010
10.10	Profit Sharing Agreement between TNS, American Charter & Marketing LLC, and Delta Group Investments, Limited dated March 26, 2010		10-K	10.10	4/15/2010
10.11	Form of Common Stock and Warrant Agreement 2010		8-K	10.1	12/20/2010
10.12	$312,500 Promissory Note between TNS and Delta Group Investments Limited dated January 26, 2011		8-K	10.2	2/22/2010
10.13	Termination of Profit Sharing Agreement dated February 21, 2011		8-K	10.1	2/22/2011
10.14	Lease Agreement between TNS and Sherwood Venture LLC dated March 15, 2011		8-K	10.1	4/6/2011
10.15	Form of Warrant A Agreement 2010		8-K	10.2	12/22/2010
10.16	Form of Warrant B Agreement 2010		8-K	10.3	12/22/2010
31.1	Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.	X

- 20 -

31.2	Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended.	X
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).	X
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).	X

- 21 -

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Total Nutraceutical Solutions, Inc.
May 23, 2011	By:	/s/ Marvin Hausman, M.D.
		Marvin Hausman, M.D. Chief Executive Officer (Principal Executive Officer and Acting Principal Financial and Accounting Officer)

- 22 -